Deutsche Bank reiterates its Hold rating on Quest Diagnostics DGX. At the same time, Deutsche Bank left its price target unchanged at $63.
In a research report published today, Deutsche Bank states, "DGX's relative under-performance to its close peer, LH, has grown
wider in recent years and, in our view, is becoming a “sore” point w/ investors. We
assume DGX's board would take the co's absolute and relative performance into
close consideration in the context of the CEO's impending employment contract
renewal." On Wednesday, Quest Diagnostics closed the day at $58.18.
Crown Castle CCI had its rating and price target maintained. At the moment, Deutsche Bank has a Buy rating and a price target of $57 on the company's stock.
In the report, Deutsche Bank states, "Crown Castle (CCI) has underperformed the S&P 500
by 12.5%, REITs by 16.3% and American Tower (AMT) by 13.0%. As a result of this
underperformance, the stock is approaching historical floor valuations and trading at
a steep discount to key comps despite a number of potential positive catalysts in
2H11." On Wednesday, Crown Castle's shares closed at $41.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in